19074
document
Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa : correlation with endoscopic lesions and adverse reactions . The aim of this study was to evaluate the effect of ibuprofen on gastric mucosa and enzymes involved in gastroprotection in healthy volunteers . Twenty-four Helicobacter pylori-negative subjects were randomized to treatment with ibuprofen or ibuprofen-arginate ( each 600 mg/6 hr during 3 days ) . Endoscopies were performed 1 week before and after treatment . Biopsies were taken from the gastric antrum and corpus for determination of prostaglandin E2 ( PGE2 ) by ELISA and cyclooxygenase ( COX-1 and COX-2 ) and nitric oxide synthase ( eNOS and iNOS ) by western blot . All subjects had at least one gastric lesion except for two individuals taking ibuprofen-arginate . Ibuprofen-arginate caused a lower rate of clinical adverse reactions than ibuprofen . Subjects with gastric lesions or adverse reactions had lower PGE2 levels . COX-1 , COX-2 , eNOS , and iNOS were detectable in all subjects . The constitutive enzymes ( COX-1 and eNOS ) did not change after treatment . COX-2 was higher in corpus than antrum and it increased after ibuprofen treatment . iNOS tended to increase mildly in the corpus in subjects with adverse reactions or endoscopic lesions . There were no significant differences between ibuprofen and ibuprofen-arginate in PGE2 , or enzymes .
19075
Intervention_Pharmacological
ibuprofen
19076
Intervention_Pharmacological
ibuprofen
19077
Intervention_Pharmacological
ibuprofen
19078
Intervention_Pharmacological
ibuprofen-arginate
19079
Intervention_Physical
Endoscopies
19080
Intervention_Physical
ELISA
19081
Outcome_Physical
cyclooxygenase and nitric oxide synthase of gastric mucosa :
19082
Outcome_Physical
endoscopic lesions
19083
Outcome_Adverse-effects
adverse reactions
19084
Outcome_Physical
gastric mucosa and enzymes involved in gastroprotection
19085
Outcome_Physical
clinical adverse reactions
19086
Outcome_Physical
gastric lesions
19087
Outcome_Physical
COX-1 , COX-2 , eNOS , and iNOS
19088
Participant_Condition
healthy
19089
Participant_Sample-size
Twenty-four
19090
Participant_Condition
Helicobacter pylori-negative